Cureus | Advances in Epigenetic Cancer Therapeutics
Histone acetyltransferases: challenges in targeting bi-substrate enzymes | Clinical Epigenetics | Full Text
HAT inhibitors in cancer therapy - ScienceDirect
Rational Combinations Using HDAC Inhibitors | Clinical Cancer Research
Histone Acetyltransferases (HATs) Involved in Non-Homologous End Joining as a Target for Radiosensitization | IntechOpen
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer | Anticancer Research
Figure 1 | Targeting epigenetics for cancer therapy | SpringerLink
Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
The role of histone deacetylases (HDACs) in human cancer - Ropero - 2007 - Molecular Oncology - Wiley Online Library
Histone deacetylase modulators provided by Mother Nature | Genes & Nutrition | Full Text
Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials | Signal Transduction and Targeted Therapy
Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells | Clinical Epigenetics | Full Text
Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT
Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases - ScienceDirect
Frontiers | Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus | Cell and Developmental Biology
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed | Future Medicinal Chemistry
Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition | Drug Metabolism & Disposition
Frontiers | Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy | Oncology
Cancers | Free Full-Text | Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer | HTML
Oxygen | Free Full-Text | Comprehension of the Relationship between Autophagy and Reactive Oxygen Species for Superior Cancer Therapy with Histone Deacetylase Inhibitors | HTML
Inhibition of histone acetyltransferase GCN5 extends lifespan in both yeast and human cell lines - Huang - 2020 - Aging Cell - Wiley Online Library
CPTH2 is a Potent Histone Acetyltransferase (HAT) Inhibitor - Network of Cancer Research
A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy | Bentham Science
Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases - ScienceDirect
HAT inhibitors in cancer therapy - ScienceDirect
Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo | Oncogenesis
Frontiers | Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy | Oncology
